Oxford/AstraZeneca vaccine likely similarly effective for UK variant as for original Covid-19 virus
Source: The Guardian.
Oxford University researchers who developed the vaccine say it has a similar efficacy against the variant first detected in Kent and the South East of the UK, compared to the original strain of Covid-19 that it was tested against.
Andrew Pollard, professor of paediatric infection and immunity, and chief investigator on the Oxford vaccine trial, said: Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus, but also protects against the novel variant, B117, which caused the surge in disease from the end of 2020 across the UK.
The pre-print from Oxford, which is yet to be peer-reviewed, found that vaccine efficacy against symptomatic positive infection was similar for the new UK variant and the previous strain, at 74.6% and 84% respectively.
Pollard said it was not possible to say whether the efficacy levels were the same or different because of overlapping confidence intervals.
Read more: https://www.theguardian.com/world/live/2021/feb/05/uk-covid-live-hotel-quarantine-delay-coronavirus-vaccine-cases-variant-boris-johnson-latest-updates